BCL6 protein degrader (Institute of Cancer Research)

N/A

Report date: 2025/03/18 18:11:17
NME

Base Information

Drug NameBCL6 protein degrader (Institute of Cancer Research)
Drug Alias NameBCL6 targeted degrader therapy (Institute of Cancer Research)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionB-cell lymphoma 6 protein inhibitors
TargetsB-cell lymphoma 6 protein
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungBreast Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesInstitute Of Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Cancer Research
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungBreast Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A